Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bryostatin 1 in Myelodysplastic Syndrome
NCT00003171Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- May 1998
- Primary completion
- Jul 1999
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bryostatin-1 in myelodysplastic syndrome (MDS), sponsored by Barbara Ann Karmanos Cancer Institute. Primary endpoint: Response Rate. Started May 1998; status: completed.
02
Drugs
bryostatin-1
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00003171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003171.